Linagliptin Explained

Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes (but not type 1) in conjunction with exercise and diet.[1] It is generally less preferred than metformin and sulfonylureas as an initial treatment. It is taken by mouth.

Common side effects include inflammation of the nose and throat. Serious side effects may include angioedema, pancreatitis, joint pain. Use in pregnancy and breastfeeding is not recommended.[2] Linagliptin is a dipeptidyl peptidase-4 inhibitor that works by increasing the production of insulin and decreasing the production of glucagon by the pancreas.

Linagliptin was approved for medical use in the United States,[3] Japan, the European Union, Canada, and Australia in 2011.[4] [5] In 2020, it was the 293rd most commonly prescribed medication in the United States, with more than 1million prescriptions.[6] [7] From August 2021 linagliptin became available as a generic medicine in the US.[8]

Medical uses

Linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Side effects

Linagliptin may cause severe joint pain.[9]

Mechanism of action

Linagliptin belongs to a class of drugs called DPP-4 inhibitors.

Names

Linagliptin is the international nonproprietary name (INN).[10] Brand names: Trajenta,[11] Tradjenta.

See also

Notes and References

  1. Neumiller JJ . Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus . The Annals of Pharmacotherapy . 46 . 3 . 358–67 . March 2012 . 22318932 . 10.1345/aph.1Q522 . 207264493 .
  2. Book: British national formulary : BNF 76. 2018. Pharmaceutical Press. 9780857113382. 680. 76.
  3. Web site: Drug Approval Package: Tradjenta (linagliptin) Tablets NDA #201280 . U.S. Food and Drug Administration (FDA) . 7 June 2011 . 3 October 2022 . 3 April 2022 . https://web.archive.org/web/20220403111238/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000TOC.cfm . live .
  4. Web site: Linagliptin Monograph for Professionals . Drugs.com . American Society of Health-System Pharmacists . 6 April 2019 . 6 April 2019 . https://web.archive.org/web/20190406231038/https://www.drugs.com/monograph/linagliptin.html . live .
  5. Web site: 10 years . Boehringer Ingelheim Limited . 3 October 2022 . 3 October 2022 . https://web.archive.org/web/20221003180613/https://pro.boehringer-ingelheim.com/products/trajenta/10years#pre2011 . live .
  6. Web site: The Top 300 of 2020 . ClinCalc . 7 October 2022 .
  7. Web site: Linagliptin - Drug Usage Statistics . ClinCalc . 7 October 2022 .
  8. Web site: Linagliptin: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) . 24 September 2021 . 25 September 2021 . https://web.archive.org/web/20210925023535/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208335 . live .
  9. Web site: DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain. U.S. Food and Drug Administration (FDA). 1 September 2015. 28 August 2015. 13 December 2019. https://web.archive.org/web/20191213203243/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain. live.
  10. Web site: International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 61 . World Health Organization . 10 November 2016 . 66 . 3 October 2020 . https://web.archive.org/web/20201003141721/https://www.who.int/medicines/publications/druginformation/innlists/RL61.pdf . live .
  11. Web site: Linagliptin: medicine to treat type 2 diabetes . NHS UK. 25 March 2022. 21 November 2022.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Linagliptin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.